Completed PHASE3 INTERVENTIONAL 2-arm NCT00563433

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Sponsor: Abeona Therapeutics, Inc

Updated 6 times since 2017 Last updated: Sep 1, 2020 Started: Aug 31, 1994 Primary completion: Jul 31, 1996 Completion: Jul 31, 1996

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetic Foot Ulcers and is currently completed. Abeona Therapeutics, Inc leads this study, which shows 6 recorded versions since 1994 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3
Sep 2020 — Oct 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Sep 2020 [monthly]

Completed PHASE3

First recorded

Aug 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abeona Therapeutics, Inc
Genaera Corporation

Data source: Abeona Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States